National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

NIH Publication No. 01-3670, May 2001 - 40 p. Introduction Background LDL Cholesterol: The Primary Target of Therapy Risk Assessment: First Step in Risk Management Method of risk assessment: counting major risk factors and estimating 10-year CHD risk Role of other risk factors in risk assessment Metabolic syndrome The link between risk assessment and cost effectiveness Primary Prevention With LDL-Lowering Therapy Secondary Prevention With LDL-Lowering Therapy LDL-Lowering Therapy in Three Risk Categories CHD and CHD risk equivalents Multiple (2+) risk factors and 10-year risk 220% Zero to one risk factor Therapeutic Lifestyle Changes in LDL-Lowering Therapy Drug Therapy to Achieve LDL-Cholesterol Goals Secondary prevention: drug therapy for CHD and CHD risk equivalents LDL-lowering drug therapy for primary prevention Benefit Beyond LDL Lowering: The Metabolic Syndrome as a Secondary Target of Therapy Management of underlying causes of the metabolic syndrome Specific Treatment of Lipid and Non-Lipid Risk Factors Special Issues Management of Specific Dyslipidemias Special Considerations for Different Population Groups Adherence to LDL-Lowering Therapy Appendix Shared Features of ATP III and ATP II Estimating 10-Year Risk for Men and Women